https://www.selleckchem.com/products/cc-122.html
05). Of the 10 subjects, 3 experienced an EGPA exacerbation during the treatment. One had a severe adverse event, requiring removal from the study. Yielding similar results to other anti-interleukin 5 biologic medications, reslizumab is generally a safe and effective treatment for EGPA that warrants further study. ClinicalTrials.gov Identifier NCT02947945. ClinicalTrials.gov Identifier NCT02947945. This review provides an overview of our current understanding of the mechanisms of food protein-induced enterocolitis syndrome (FPIES). To ca